Alastair Riddell

Dr. Riddell joined the board of directors in September 2015. He is also currently Chairman of a private UK biotech, Nemesis Biosciences Ltd, Chairman of a UK AIM listed medical imaging company Feedback plc and Chairman of the South West Academic Health Science Network, which fosters links between the NHS, industry, and universities. He was also on the board of directors of another US private company, Skyline Vet Pharma until April 2017. Dr. Riddell has over 30 years of experience in the pharmaceutical, life science, and biotech industries, and 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology, and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent 5 years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for 3 UK biotech companies, Pharmagene, Paradigm Therapeutics, and Stem Cell Sciences; in these roles, he was the principal involved in significant fundraising including an IPO on UK’s main list and trade sales to Takeda in Japan and Stem Cells Inc. in the USA. He has since had several roles in UK government initiatives related to promoting cooperation between pharmaceutical companies and the NHS and assessing projects for funding with Innovate UK. He began his career as a medical doctor in a variety of hospital specialties and in general practice. He was recently awarded a Doctorate of Science, Honoris Causa by Aston University.